1.55
0.00 (0.00%)
| Previous Close | 1.55 |
| Open | 1.48 |
| Volume | 196,701 |
| Avg. Volume (3M) | 571,098 |
| Market Cap | 54,582,244 |
| Price / Book | 13.65 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2026 |
| Diluted EPS (TTM) | -0.990 |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | -10.08 M |
| Levered Free Cash Flow (TTM) | -12.28 M |
| Return on Assets (TTM) | -263.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | OS Therapies Incorporated | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.25 |
|
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 33.38% |
| % Held by Institutions | 1.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stratos Wealth Advisors, Llc | 31 Dec 2025 | 13,817 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies |
| 02 Feb 2026 | Announcement | OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma |
| 15 Jan 2026 | Announcement | OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma |
| 14 Jan 2026 | Announcement | OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary |
| 12 Jan 2026 | Announcement | OS Therapies Enters into Warrant Inducement Agreements |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |